Reported 1 day ago
Moderna, Inc. (MRNA) has experienced a significant decline of over 35% in its share price year-to-date, primarily due to decreased demand for its COVID-19 vaccines and challenges in its product pipeline. Despite being recognized as one of the best S&P 500 stocks with potential upside, the company's lowered revenue forecasts and negative investor sentiment have overshadowed its performance. Analysts remain cautious yet optimistic about a potential recovery as the company makes progress in clinical treatments.
Source: YAHOO